659 results on '"De Marinis, Laura"'
Search Results
2. Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy
3. Vitamin D in pituitary driven osteopathies
4. Nuove frontiere terapeutiche nel craniofaringioma
5. Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience
6. De-escalation treatment with pasireotide for acromegaly: a long-term experience
7. The immune microenviroment in somatotropinomas: from biology to personalized and target therapy
8. Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients?
9. Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience
10. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly
11. Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results
12. GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study.
13. Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients.
14. A pituitary metastasis from occult neuroendocrine carcinoma
15. The pathogenic RET val804met variant in acromegaly: a new clinical phenotype?
16. Acromegaly and morris syndrome: description of a clinical case
17. Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot monocenter experience
18. Pitfalls in diagnosis of the pituitary stalk lesion: infundibulo-neurohypophysitis or germ cell tumor?
19. The differential diagnosis between cushing's disease and pseudocushing syndrome in a pre-agonic patient
20. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
21. Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study
22. Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues
23. Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study
24. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
25. Empty sella syndrome: Multiple endocrine disorders
26. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort
27. THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
28. THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
29. THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
30. THU093 Pituitary Enlargement And Hypopituitarism In Patients Treated With Immune Checkpoint Inhibitors: Two Sides Of The Same Coin?
31. The role of the GH receptor polymorphisms as a prognostic factor of vertebral fractures in acromegalic patients resistant to first-generation SSAs and treated with Pegvisomant or Pasireotide Lar
32. L’immagine medico-nucleare recettoriale guida la terapia del residuo post-chirurgico degli adenomi ipofisari non secernenti
33. Cholecalciferol use is associated with a decreased risk of incident morphometric vertebral fractures in acromegaly
34. Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review
35. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort
36. The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?
37. Dalla cardiochirurgia alla neurochirurgia: un caso di apoplessia ipofisaria dopo bypass aorto-coronarico con chiara evidenza RMN
38. Somatotropic Axis in Human Aging
39. Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis
40. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly
41. Bone safety of dual-release hydrocortisone in patients with hypopituitarism
42. Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors
43. Pancreas, An Unusual Metastatic Site In A Long-term Indolent Surviving Case, Under Somatostatin Analogues Therapy, Of Medullary Thyroid Carcinoma: A Case Report And Review Of Cases Documented In Literature
44. Inflammatory infiltrate in wild-type and non-wild-type GNAS somatotropinomas
45. Cushing's disease: a rare case of long-term pasireotide therapy
46. Somatostatin Analogues or Active Surveillance in Sporadic and MEN1 associated Non-functioning Pancreatic Neuroendocrine Tumors
47. De-escalation treatment with pasireotide for aggressive acromegaly: A long-term experience
48. The Role of the GH Receptor Polymorphism as Prognostic Factor of Vertebral Fractures in Acromegaly Patients Resistant to First Generation SSAs and Treated with GH Receptor Antagonist or Second-Generation Somatostatin Ligand
49. The acro-TIME score: a new clinical, pathological and immune integrative approach to early identify acromegaly patients resistant to treatment with first generation somatostatin ligands
50. Pasireotide LAR Treatment for Non-functioning Pituitary Adenoma: A Case Report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.